Wójcik Sławomir, Engel W King, McFerrin Janis, Askanas Valerie
USC Neuromuscular Center, Department of Neurology, University of Southern California Keck School of Medicine, Good Samaritan Hospital, 637 S. Lucas Ave, Los Angeles, CA, 90017-1912, USA.
Acta Neuropathol. 2005 Aug;110(2):173-7. doi: 10.1007/s00401-005-1035-3. Epub 2005 Jun 28.
Myostatin is a negative regulator of muscle mass and strength. Sporadic inclusion-body myositis (s-IBM) is the most common degenerative muscle disease of older persons and is characterized by pronounced muscle wasting. s-IBM is of unknown etiology and pathogenesis, and it lacks definitive treatment. We have now demonstrated in samples from 12 s-IBM biopsies that: (1) by light and electron microscopic immunocytochemistry, myostatin/myostatin precursor is accumulated within muscle fibers and co-localized with amyloid-beta (Abeta); (2) by immunoblots, both myostatin and myostatin precursor are increased; and (3) by immunoprecipitation, myostatin precursor complexes with Abeta. Our study suggests that myostatin/myostatin precursor, either alone, or bound to Abeta, may play a novel role in the pathogenesis of s-IBM.
肌肉生长抑制素是肌肉质量和力量的负调节因子。散发性包涵体肌炎(s-IBM)是老年人中最常见的退行性肌肉疾病,其特征是明显的肌肉萎缩。s-IBM的病因和发病机制尚不清楚,且缺乏确切的治疗方法。我们现已在12例s-IBM活检样本中证实:(1)通过光镜和电镜免疫细胞化学检测,肌肉生长抑制素/肌肉生长抑制素前体在肌纤维内积聚,并与β淀粉样蛋白(Aβ)共定位;(2)通过免疫印迹法检测,肌肉生长抑制素和肌肉生长抑制素前体均增加;(3)通过免疫沉淀法检测,肌肉生长抑制素前体与Aβ形成复合物。我们的研究表明,肌肉生长抑制素/肌肉生长抑制素前体,无论是单独存在还是与Aβ结合,可能在s-IBM的发病机制中发挥新的作用。